ResMed Q4 revenue $1.22B (+9% YoY); EPS $1.98; dividend up 10% to $0.53

RESMED INC

2024-FY EPS reported $6.92 revenue$4,685,297,000

Q4 FY2024 revenue $1,223.2M (+9% YoY, +10% constant currency); gross margin 58.5% (+350 bps).
GAAP diluted EPS $1.98 (+27% YoY); non-GAAP diluted EPS $2.08 (+30% YoY).
Operating cash flow $440M; debt repayments of $300M in Q4; FY2024 operating cash flow $1.4B.
Quarterly dividend increased 10% to $0.53 per share (payable Sept 19, record Aug 15).
Investor Day announced for September 30, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.